CytoDyn Inc. (CYDY) Fair Value 2026

CYDY · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-27, CytoDyn Inc. (CYDY) trades at $0.23, versus a $0.00 median fair value across its 3 active models — 98.1% below the current price. QOC: 5.1/10. Value Trap Risk: 43/100 (WARN). 3/13 models active. Within that set, the Bayesian DCF component alone returns $0.00.

Key Facts

Ticker
CYDY
Price
$0.23
Quality Score
5.1/10
Value Trap Risk
43/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

Is CytoDyn Inc. (CYDY) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, CytoDyn Inc. (CYDY) appears overvalued as of : the median of 3 independent fair value estimates is $0.00, 98.1% below the current price of $0.23. Estimates range from $0.00 to $0.01. CYDY scores 5.1/10 on fundamental quality and 43/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CYDY’s -98.1% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy CytoDyn Inc. Stock in 2026? →

What Fair Value Does Each Model Give CYDY?

3 Intrinsic Value Models vs. Current Price ($0.23)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.00 -98.4%
Relative · Medium Conviction
 $0.01 -96.8%
Intrinsic · Low Conviction
 $0.00 -98.1%

All Models Active

All 3 models are displayed above.

What Is CYDY's Fair Value Range?

Spread across 3 independent models · $0.00 to $0.01

CirclFi's 3 active models place CytoDyn Inc. (CYDY) between $0.00 and $0.01 per share, a spread of 85% of the median. The median of that range — $0.00 — is the fair value CirclFi publishes for CYDY, against a current price of $0.23.

Low · Bayesian DCFHigh · Regime Cross
$0.00median $0.00$0.01
Where the range comes from
Most bearish modelBayesian DCF$0.00
Most bullish modelRegime Cross-Sectional$0.01
Model agreement0 bullish · 3 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on CYDY, not a CirclFi price target. How each model works →

What Is CytoDyn Inc. (CYDY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, CytoDyn Inc.'s intrinsic value is estimated at $0.00, suggesting the stock is overvalued at its current price of $0.23. With 3 out of 3 models flagging downside (-98.1% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About CYDY?

3 of 13 models are currently active for CYDY. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for CYDY is $0.00 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.00 on its own, implying -98.4% downside from the current price. See which stocks rank higher →

How Does CYDY Rank in Biotechnology?

Among 620 Biotechnology stocks, CYDY ranks #294 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, CytoDyn Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating CYDY should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CYDY a Value Trap?

CirclFi's Value Trap algorithm assigns CYDY a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for CytoDyn Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, CytoDyn Inc.'s fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+1.6% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CYDY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CYDY's 3 active models, average confidence is 10%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CytoDyn Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IMNMImmunome, Inc.QOC 5.1JUNSJupiter Neurosciences, Inc.QOC 5.1KRROKorro Bio, Inc.QOC 5.1SERSerina Therapeutics, Inc.QOC 5.1DYNDyne Therapeutics, Inc.QOC 5.1SLSSELLAS Life Sciences Group, Inc.QOC 5.1PEPGPepGen Inc.QOC 4.5TLSATiziana Life Sciences LtdQOC 2.5AARDAardvark Therapeutics, Inc.QOC 6.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IMNM · JUNS · KRRO · SER · DYN · SLS · PEPG · TLSA · AARD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CYDY?

6 companies across all industries closest to CYDY’s Quality of Company score of 5.1/10.

WRDWeRide Inc.QOC 5.1MKZRMacKenzie Realty Capital, Inc.QOC 5.1AECAnfield Energy Inc.QOC 5.1DTGIDigerati Technologies, Inc.QOC 5.1SEGSeaport Entertainment Group Inc.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: WRD · MKZR · AEC · DTGI · SEG · NVDA

Where Does CYDY Sit in CirclFi's Biotechnology Rankings?

CYDY is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About CytoDyn Inc.’s Valuation?

What is CytoDyn Inc.'s intrinsic value in 2026?

CirclFi puts CytoDyn Inc. (CYDY)'s intrinsic value at $0.00 — the median of 3 independent model estimates as of 2026-08-27, ranging from $0.00 to $0.01. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.00 on its own. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CYDY overvalued or undervalued right now?

At $0.23, 0 of 3 active models suggest CYDY may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $0.00, 98.1% below the current price of $0.23 — a consensus view that CYDY is overvalued. The assessment depends on which methodology best fits CytoDyn Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for CYDY?

CytoDyn Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CYDY?

CirclFi analyzes CYDY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CYDY?

Of the 3 models currently active on CYDY, Regime Cross-Sectional is the most bullish at $0.01 per share, and Bayesian DCF is the most bearish at $0.00. CirclFi's published fair value for CYDY is the median of that range, $0.00, not either extreme. The gap between the two ends equals 85% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is CYDY a value trap in 2026?

CytoDyn Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, CytoDyn Inc. (CYDY) has a median fair value of $0.00 — 98.1% below the current price of $0.23 — as of 2026-08-27.” Source: circlfi.com/stock/CYDY/ · Methodology
Primary sources for this CYDY valuation
  • Financial statements: CytoDyn Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001175680) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CYDY as of ; valuations recomputed .